Aruna Kamineni, PhD, MPH, came to Kaiser Permanente Washington Health Research Institute in 2009 with a wealth of experience in chronic disease epidemiology. Dr. Kamineni has expertise in using case-control methods to evaluate screening efficacy, and her research focuses on addressing evidence gaps for clinical guidelines, particularly for cervical and colorectal cancer prevention. A substantial portion of her work has focused on developing infrastructure and methods for research using electronic clinical and administrative health care data.
Since 2011, Dr. Kamineni has participated in the National Cancer Institute’s Population-based Research to Optimize the Screening Process (PROSPR) consortium to evaluate and improve cancer screening in U.S. community settings. As a principal investigator for multisite cervical and colorectal cancer PROSPR Research Centers, Dr. Kamineni is leading and collaborating on work to determine how to optimally use screening tests and consider how to tailor screening for population subgroups.
Dr. Kamineni’s research goals include studying the impact of human papillomavirus (HPV) DNA testing and HPV vaccination on cervical cancer and screening programs. Multidisciplinary collaboration is a valued and important driver of Dr. Kamineni’s research and she embraces a team science approach to optimizing cancer prevention.
Cervical cancer; colorectal cancer; screening; disparities
Electronic clinical and administrative data infrastructure development for research; case-control studies; team science
Feigelson HS, Clarke CL, Van Den Eeden SK, Weinmann S, Burnett-Hartman AN, Rowell S, Scott SG, White LL, Ter-Minassian M, Honda SAA, Young DR, Kamineni A, Chinn T, Lituev A, Bauck A, McGlynn EA. The Kaiser Permanente Research Bank Cancer Cohort: a collaborative resource to improve cancer care and survivorship. BMC Cancer. 2022;22(1):209. doi: 10.1186/s12885-022-09252-6. PubMed
Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC. Variation in the receipt of human papilloma virus co-testing for cervical screening: individual, provider, facility and healthcare system characteristics. Prev Med. 2022 Jan;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 8. PubMed
Silver M, Anderson ML, Beaber EF, Haas JS, Kobrin S, Pocobelli G, Skinner CS, Tiro JA, Kamineni A. De-implementation of cervical cancer screening before age 21. Prev Med. 2021 Sep 29:106815. doi: 10.1016/j.ypmed.2021.106815. Online ahead of print. PubMed
Castanon A, Kamineni A, Elfstrøm KM, Lim AW, Sasieni P. Exposure definition in case-control studies of cervical cancer screening: a systematic literature review. Cancer Epidemiol Biomarkers Prev. 2021 Sep 14:cebp.0376.2021. doi: 10.1158/1055-9965.EPI-21-0376. [Epub ahead of print]. PubMed
Croswell JM, Corley DA, Lafata JE, Haas JS, Inadomi JM, Kamineni A, Ritzwoller DP, Vachani A, Zheng Y. Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. Prev Med. 2021 Oct;151:106595. doi: 10.1016/j.ypmed.2021.106595. Epub 2021 Jun 30. PubMed
Puricelli Perin DM, Elfström KM, Bulliard JL, Burón A, Campbell C, Flugelman AA, Giordano L, Kamineni A, Ponti A, Rabeneck L, Saraiya M, Smith RA, Broeders MJM; International Cancer Screening Network. Early assessment of the first wave of the COVID-19 pandemic on cancer screening services: the International Cancer Screening Network COVID-19 survey. Prev Med. 2021 Oct;151:106642. doi: 10.1016/j.ypmed.2021.106642. Epub 2021 Jun 30. PubMed
Puricelli Perin DM, Christensen T, Burón A, Haas JS, Kamineni A, Pashayan N, Rabeneck L, Smith R, Elfström M, Broeders MJM; International Cancer Screening Network ICSN. Interruption of cancer screening services due to the COVID-19 pandemic: lessons from previous disasters. Prev Med Rep. 2021 May 17:101399. doi: 10.1016/j.pmedr.2021.101399. Online ahead of print. PubMed
Burger EA, Jansen EE, Killen J, Kok IM, Smith MA, Sy S, Dunnewind N, G Campos N, Haas JS, Kobrin S, Kamineni A, Canfell K, Kim JJ. Impact of COVID-19-related care disruptions on cervical cancer screening in the United States. J Med Screen. 2021 Jun;28(2):213-216. doi: 10.1177/09691413211001097. Epub 2021 Mar 17. PubMed
Kamineni A, Blasi PR, Gundersen GD, Oliver M, Dunn JB, Galloway DA, Madeleine MM. Barriers to human papillomavirus vaccine series completion among insured individuals in an integrated healthcare setting. Infect Dis (Auckl). 2021 May 20;14:11786337211018712. doi: 10.1177/11786337211018712. eCollection 2021. PubMed
Ghai NR, Jensen CD, Merchant SA, Schottinger JE, Lee JK, Chubak J, Kamineni A, Halm EA, Skinner CS, Haas JS, Green BB, Cannizarro NT, Schneider JL, Corley DA. Primary care provider beliefs and recommendations about colorectal cancer screening in four healthcare systems. Cancer Prev Res (Phila). 2020 Nov;13(11):947-958. doi: 10.1158/1940-6207.CAPR-20-0109. Epub 2020 Jul 15. PubMed
Research informs care as Kaiser Permanente Washington, exceeding 80 percent screening rate, launches home-based 'FIT First' pilot.
Drs. Kamineni and Chubak are among leaders of 2 new large PROSPR awards from NCI for cervical and colorectal cancer screening research.
Read it in News and Events.
A Kaiser Permanente-led BCSC study is among the largest ever to evaluate adding MRI surveillance for breast cancer survivors.